Moderna announced in a statement that its Covid vaccine is 94.5% effective.
After that of AstraZeneca and the University of Oxford, the EMA (European Medicines Agency) has started analyzing the data of the mRna-1273 anti-Covid vaccine developed by Moderna Biotech Spain, a company controlled by the American Moderna.
As the EMA specifies on its website, it was decided to start with the rolling review procedure, the first step of the approval process, based on the preliminary results of the non-clinical studies and the first clinical studies done on adults, which seem that the vaccine stimulates the production of antibodies and immune T cells against the SarsCov2 virus.
The Moderna company has announced a longer shelf life for its mRNA-1273 vaccine candidate against COVID-19 at "refrigeration temperatures".
The vaccine candidate is expected to remain stable at standard refrigeration temperatures between 2 ° and 8 ° C for 30 days, compared to the previous estimate of 7 days.
In addition, long-term transport and storage conditions are expected at standard freezer temperatures of -20 ° C for 6 months.
The EMA and the national regulatory agencies of European countries have prepared a special plan for monitoring the safety of anti-Covid vaccines, on how to collect and analyze the information that will emerge once it is authorized.
companies will have to submit monthly reports on their safety.
Phase 3 of the trial for another coronavirus vaccine candidate kicks off
.
It belongs to Janssen, a pharmaceutical company headed by the chemical multinational Johnson & Johnson.
It is the third to arrive at this passage among those developed in Great Britain, after the prototype developed by the University of Oxford together with AstraZeneca with the collaboration of the Italian Irbm of Pomezia (first ever in the West to enter phase 3 ) and that of Novavax.
Phase 3 of the Janssen vaccine, confirms British Health Minister Matt Hancock, begins today and will involve 7,000 volunteers in the UK and 23,000 in other countries.
It is a vaccine model "very similar to that of Oxford / AstraZeneca," Saul Faust, director of the Southampton laboratory that coordinates the research project, told SkyNews.
